More articles from Cancer Diagnosis and Management
- Chronic lymphocytic leukemia: A brief review
CLL, the most common type of leukemia, is often discovered incidentally when a routine complete blood count is performed. This paper reviews the pathology, diagnosis, and treatment of CLL.
- Stereotactic breast biopsy: A less-invasive option
Percutaneous core needle biopsy, guided by digital three-dimensional x-ray imaging, offers a reasonable alternative to standard surgical biopsy.
- Assessing and minimizing reproductive risks of cancer chemotherapy
Now that more children and young adults are surviving malignant diseases, a new problem is arising: the reproductive effects of intensive chemotherapy.
- Inpatient management of acute leukemia
In treating acute leukemia, there are four medical emergencies that require immediate attention: infection, hemorrhage, hyperleukocytosis, and tumor lysis syndrome.
- What primary care physicians should know about the toxicityof cancer chemotherapy
Although symptomatic side effects of chemotherapy reduce a patient’s quality of life, organ-system effects are potentially more serious.
- Ethical issues in clinical trials in oncology
Ethical questions can arise in a number of situations in oncology clinical trials.
- Calculating cancer risk: It is harder than it seems
Many factors make cancer risk assessment difficult, especially when determining the risk for an individual.
- From serendipity to design: the evolution of drug development in oncology
Although the screening of natural products remains the major method of discovering new anticancer drugs, new techniques of computer-aided drug design and combinatorial synthesis will also play a role.
- The dilemma of evaluating and treating cancer of unknown primary site
In 5% to 10% of cancer cases, the initial presentation reflects metastases and not the primary lesion. How aggressively should one search for the tumor site?
- When and how to use serum tumor markers in clinical practice
Clinicians have long wanted a simple test sensitive enough to detect cancer in its early stages, yet specific enough to not produce false-positive results. Unfortunately, no such ideal test exists, or is likely to.